SU
Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
$41.38 +0.17% (+$0.07)
1M -15.60%
Market Cap $2.40B
P/E Ratio -
Div. Yield -
ROE 10.42%
Bulios Fair Price
$30.55
26.2% downside
Current Price
$41.38
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SUPN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
31 /100
Expensive P/B 2.33x
P/FCF 127.84x
P/S 2.89x
Growth
25 /100
Declining FCF growth 26.62%
Book val. growth 6.21%
Rev. growth 2.52%
Profitability
26 /100
Weak FCF margin 2.26%
Op. margin 13.46%
Gross margin 88.07%
Quality
7 /100
Poor Asset turnover 0.58x
ROA 7.69%
ROIC 9.12%
Debt
69 /100
Low Current ratio 2.08x
Int. coverage -50.79x
Debt/Equity 0.04x
Stability
50 /100
Moderate Profitable years 0
EPS volatility 3,229.95%
Beta 0.56x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SUPN
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jack A. Khattar
Employees
778
Headquarters
Rockville
Upcoming events
03 NOV
Earnings
Upcoming earnings report